Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.46 |
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
| ▸ | HTR2B | P41595 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16706745 | 0.96 | RAB9A (0.46) | HTR2AHTR2CHTR2BRAB9AMEN1 | |
| SCHEMBL16710105 | 0.94 | RAB9A (0.51) | HTR2AHTR2CHTR2BRAB9AKMT2A | |
| SCHEMBL16706725 | 0.91 | RAB9A (0.49) | HTR2AHTR2CHTR2BRAB9AMEN1 | |
| SCHEMBL16710113 | 0.90 | RAB9A (0.44) | RAB9AMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL16706810 | 0.89 | KMT2A (0.43) | RAB9AMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL16710095 | 0.89 | TP53 (0.52) | HTR2AHTR2CHTR2BRAB9AKMT2A | |
| SCHEMBL16706739 | 0.88 | KMT2A (0.43) | RAB9AMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL16710028 | 0.88 | KDM4E (0.46) | MEN1KMT2AMAPTSMN1; SMN2TP53 | |
| SCHEMBL16706690 | 0.88 | SMN1; SMN2 (0.46) | HTR2AHTR2CHTR2BKMT2AMAPT | |
| SCHEMBL16710109 | 0.87 | HTR2A (0.52) | HTR2AHTR2CHTR2BMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951033-B2 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2018-04-24 | — | — | US | disclosed |
| US-20170158657-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2017-06-08 | — | — | US | disclosed |
| US-9556111-B2 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2017-01-31 | — | — | US | disclosed |
| US-20150133510-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158657-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | TNNI3, TNNT2, MYLK2 | HTR2A 911/4885HTR2C 1879/4885HTR2B 2750/4885 |
| US-20150133510-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | TNNI3, TNNT2, MYLK2 | HTR2A 476/4885HTR2C 1443/4885HTR2B 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.